Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ALXOthis companyALX Oncology Holdings Inc.	$1.22	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
ANNXAnnexon, Inc.	$4.27	-3.75×	3.68×	0×	-3.14×	-80.0%	0.0%	0.0%	0.0%	-97.7%	-91.0%	-24.0%	0.12×	0.66×	0×	5.68×	0.0%	1	-1.2	2	C
GLUEMonte Rosa Therapeutics, Inc.	$10.46	-26.58×	4.41×	8.31×	-29.87×	222.9%	93.2%	-43.8%	-31.2%	-16.6%	-13.6%	-2.7%	0.17×	2.89×	0×	6.12×	0.0%	2	1.69	2	C+
KYMRKymera Therapeutics, Inc.	$134.33	-21.09×	4.16×	167.51×	-20.76×	-99.8%	100.0%	-891.3%	-794.4%	-19.7%	-20.9%	-3.6%	0.05×	0.91×	-1,403.21×	10.47×	0.0%	4	41.46	1	C-
NKTXNkarta, Inc.	$1.44	-1.31×	0.44×	0×	-1.83×	-132.8%	0.0%	0.0%	0.0%	-33.3%	-31.2%	-65.7%	0.24×	-0.39×	0×	12.69×	0.0%	1	-2.81	2	C
STOKStoke Therapeutics, Inc.	$26.76	-264.5×	5.33×	10.19×	-351.59×	-260.5%	100.0%	-11.2%	-3.7%	-2.0%	-5.7%	2.4%	0.01×	15.88×	-2,287.78×	5.28×	0.0%	3	15.59	1	D+
Peer median	—	-21.09×	4.16×	8.31×	-20.76×	-99.8%	93.2%	-11.2%	-3.7%	-19.7%	-20.9%	-3.6%	0.12×	0.91×	0×	6.12×	0.0%	2	1.69	2	—